Drug Profile
TRN 157
Alternative Names: TRN-157Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Theron Pharmaceuticals
- Class Antiasthmatics; Antibronchitics; Bronchodilators
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Asthma
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in USA (Inhalation, Aerosol)
- 05 Sep 2017 TRN 157 is still in phase II trials for Asthma in USA
- 01 Mar 2016 Theron Pharmaceuticals completes a phase II trial in Asthma in USA (Inhalation) (NCT02382510)